FAA proposes ending special issuance for non-insulin diabetes pilots

Overview

Updated 7 days ago

The Federal Aviation Administration proposed a rule on September 4 that would let pilots with non-insulin dependent diabetes get medical certificates from examiners at the time of their exam, instead of waiting months for FAA headquarters review. The regulatory language requiring that review dates to 1959.

The proposal removes "or any other hypoglycemic drug" from the medical standards for first-, second-, and third-class airman certificates. Pilots who use insulin to manage diabetes still face the special issuance requirement, and examiners can defer higher-risk cases to FAA medical staff. The FAA estimates 3,000 applicants a year would qualify.

Why it matters

Pilots with non-insulin diabetes could get medical certificates on exam day instead of waiting months, a change first possible since 1959.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

3,000

Annual applicants who could get AME-issued certificates

Estimated cases per year that would bypass the special issuance process under the proposed rule.

$39.7M–$80.2M

Estimated 5-year industry cost savings

Low and high case labor-hour savings scenarios over five years, before discounting.

Years the current regulatory language has stood

Adopted in 1959, the rule has not been updated despite major advances in diabetes treatment.

1,200

Special issuance cases that would transition to AME handling

Existing NIDDM cases currently followed under special issuance that could shift to examiners under the proposal.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Organizations Involved

Federal Aviation Administration (FAA)

Federal Agency

Proposing the medical certification rule change

US agency that regulates civil aviation, including pilot medical certification.

FAA Office of Aerospace Medicine

Agency Subdivision

Would see reduced special issuance workload if rule is finalized

FAA division that reviews medical certification appeals and special issuance cases.

Timeline

January 1959 September 2026

2 events Latest: September 4th, 2026 · 1 week ago

September 2026
FAA publishes proposed rule to remove NIDDM from special issuance
Latest Rulemaking

Agency proposes deleting "or any other hypoglycemic drug" from part 67 medical standards, letting examiners clear non-insulin diabetes applicants at exam time.
September 4th, 2026
January 1959
Medical standards adopt hypoglycemic drug disqualification
Regulation

FAA adopts rule language treating any diabetes requiring insulin or other hypoglycemic drugs as potentially disqualifying.
January 1st, 1959

Scenarios

FAA finalizes non-insulin diabetes rule as proposed

Likely Resolves by End of 2027

Discussed by: The FAA's own cost-benefit analysis in the NPRM

The comment period closes without major objections. The FAA publishes a final rule in 2027 removing "or any other hypoglycemic drug" from part 67 medical standards. Aviation medical examiners begin issuing certificates to qualified NIDDM applicants at exam time using general medical standards. Insulin-treated pilots keep the special issuance pathway, and examiners can still defer higher-risk NIDDM cases to FAA medical staff.

FAA narrows the rule during comment period

Possible Resolves by End of 2027

Discussed by: Past FAA part 67 rulemakings and the AME diabetes guide

Comments from medical organizations or pilot safety groups push the FAA to add conditions: specific A1C thresholds, limitations on certain drug classes with hypoglycemia risk, or a requirement for treating physician statements. The final rule still removes the blanket disqualification but adds case-level requirements beyond the September 2026 proposal.

Rule stalls without final action

Uncertain Resolves by End of 2027

Discussed by: Historical pattern of FAA rulemaking delays and administration transitions

The comment period closes but the FAA does not publish a final rule by the end of 2027. Priorities shift with the January 2027 administration transition, and the docket remains open without action. The special issuance process continues unchanged for all NIDDM applicants.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

1959

The 1959 medical standard

The FAA adopted regulatory language treating any diabetes requiring insulin or another hypoglycemic drug as potentially disqualifying. At the time, treatment options were limited and the agency had little data on how diabetics performed as pilots.

Then

Diabetics needed individual waivers from FAA medical staff to fly.

Now

Created a 67-year-old framework that medical practice far outpaced. Modern treatments like metformin, GLP-1 agonists, and SGLT2 inhibitors now control most type 2 diabetes without insulin.

Why this matters now

The exact regulatory language from 1959 is what the September 2026 proposal would change.

1995–2013

The diabetes treatment revolution

Metformin became the standard first-line therapy in the mid-1990s, followed by GLP-1 receptor agonists and SGLT2 inhibitors in the 2000s and 2010s. These drugs manage blood glucose effectively without the hypoglycemia risk historically associated with insulin and sulfonylureas.

Then

Most type 2 diabetes patients gained non-insulin options with better safety profiles.

Now

Diabetes-related cardiovascular events and severe hypoglycemia declined, changing the risk calculus for pilot certification.